International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Revolutionizing Cancer Care: Liquid Biopsy Redefining Surgical Biopsy Paradigms

Md Ashif[1], Ramiza Akram[2]

[1]Clinical Research Scholar, Teerthanker Mahaveer College of Pharmacy, Moradabad
[2]Research Scholar, Jamia Hamdard University, New Delhi

Abstract
Liquid biopsy, a non-invasive method for analyzing circulating biomarkers in bodily fluids, has garnered significant interest as a potential alternative to traditional surgical tissue biopsy in oncology. This review explores the current landscape of liquid biopsy technologies, their clinical applications, and their potential to complement or replace surgical tissue biopsy in cancer diagnosis, treatment monitoring, and prognostication. We examine the various analytes detected in liquid biopsies, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and microRNAs, and discuss their utility in detecting genetic alterations, assessing treatment response, and monitoring disease progression. Furthermore, we compare the advantages and limitations of liquid biopsy with surgical tissue biopsy, highlighting factors such as invasiveness, accessibility, and the ability to capture tumor heterogeneity. We also address ongoing challenges in standardization, sensitivity, and specificity of liquid biopsy assays and discuss future directions aimed at optimizing their clinical utility. Overall, this review provides insights into the evolving role of liquid biopsy as a potential alternative to surgical tissue biopsy in oncology and underscores its potential to improve patient care and outcomes.

Keywords: Liquid biopsy, Oncology, Precision medicine, Non-invasive diagnostics, CTCs, Biomarkers, Cancer diagnosis.

1. Introduction

Cancer remains one of the most challenging diseases to diagnose and treat, with traditional biopsy methods often presenting limitations in terms of invasiveness, sampling bias, and inability to capture tumor heterogeneity. In recent years, the emergence of liquid biopsy has revolutionized the field of oncology by offering a minimally invasive and comprehensive approach to cancer detection and monitoring. Liquid biopsy, also known as fluid biopsy, involves the analysis of biomarkers present in bodily fluids such as blood, urine, and cerebrospinal fluid to provide insights into the presence and characteristics of tumors. This review article aims to explore the historical evolution, technological advancements, clinical applications, challenges, and future directions of liquid biopsy in the context of cancer research and clinical practice.

Cancer remains one of the most formidable challenges in modern medicine, with its diagnosis and treatment often characterized by invasive procedures and complex, multifaceted approaches. Traditional methods for diagnosing and monitoring cancer, such as tissue biopsies and imaging techniques, while

valuable, are not without limitations. These limitations include their invasive nature, potential risks to patients, and challenges in obtaining real-time, dynamic information about the disease.

In recent years, a revolutionary approach has emerged that promises to transform the landscape of cancer diagnostics and monitoring: liquid biopsy. Unlike traditional tissue biopsies that require the extraction of tissue samples directly from the tumor site, liquid biopsy harnesses the power of minimally invasive sampling techniques to analyze various biomarkers present in bodily fluids such as blood, urine, saliva, and cerebrospinal fluid.

At the heart of liquid biopsy lies the concept of circulating biomarkers, which are molecular signatures shed by tumors into the bloodstream or other bodily fluids. These circulating biomarkers include circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, and microRNAs, among others. By capturing and analyzing these biomarkers, liquid biopsy offers a non-invasive and potentially more comprehensive means of interrogating the molecular landscape of cancer.

The appeal of liquid biopsy lies not only in its minimally invasive nature but also in its ability to provide a dynamic and holistic view of the disease. Unlike tissue biopsies, which offer a snapshot of the tumor's molecular profile at a single point in time, liquid biopsy enables serial monitoring of the tumor's molecular evolution and response to treatment. This real-time, longitudinal assessment has profound implications for guiding treatment decisions, monitoring treatment response, detecting minimal residual disease, and identifying the emergence of treatment-resistant clones.

Liquid biopsy holds promise across the continuum of cancer care, from early detection and diagnosis to treatment selection, monitoring, and surveillance. In the realm of early cancer detection, liquid biopsy offers the potential to detect tumors at an earlier, more curable stage, when treatment interventions are most effective. Moreover, liquid biopsy can provide valuable insights into tumor heterogeneity, allowing clinicians to tailor treatment strategies to individual patients based on the unique molecular characteristics of their tumors.

Furthermore, liquid biopsy has the potential to overcome several challenges associated with tissue biopsies, particularly in the context of metastatic or inaccessible tumors. By virtue of its minimally invasive nature, liquid biopsy can be performed more frequently and with greater ease, enabling more frequent monitoring of disease progression and treatment response.

Despite its immense potential, liquid biopsy is not without its challenges and limitations. Technical hurdles related to sensitivity, specificity, and standardization remain significant barriers to widespread clinical adoption. Moreover, regulatory and reimbursement considerations, as well as the need for robust validation in large-scale clinical trials, are critical factors that must be addressed to realize the full clinical utility of liquid biopsy.

2. Historical Perspective

The concept of liquid biopsy can be traced back to early attempts to detect cancer cells in peripheral blood samples dating back to the late 19th century. However, it wasn't until the late 20th century that

significant progress was made in developing techniques for isolating and analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA). Milestones in liquid biopsy research include the discovery of genetic mutations in cfDNA from cancer patients and the development of technologies such as polymerase chain reaction (PCR) and next-generation sequencing (NGS) that enable the sensitive detection of tumor-derived biomarkers in bodily fluids.

3. Types of Liquid Biopsy

Liquid biopsy encompasses various biomarkers that can be analyzed to provide valuable information about the presence, characteristics, and evolution of tumors. These biomarkers include circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, circulating tumor DNA (ctDNA), and RNA (mRNA, miRNA). Each biomarker offers unique insights into different aspects of cancer biology, such as tumor heterogeneity, genomic alterations, and treatment response.

In a liquid biopsy, there are several specific parameters that researchers and doctors look for:

1. Circulating Tumor Cells (CTCs): These are cancer cells that have broken away from the primary tumor and are circulating in the bloodstream.
2. Cell-Free DNA (cfDNA): Small pieces of DNA that are released into the bloodstream by dying cancer cells.
3. Exosomes: Tiny vesicles released by cancer cells that contain genetic material, proteins, and other molecules.
4. Circulating Tumor DNA (ctDNA): Fragments of DNA shed by tumor cells into the bloodstream.
5. RNA: Messenger RNA (mRNA) or microRNA (miRNA) that can provide information about gene expression patterns in cancer cells.

4. Comparison between liquid biopsy and surgical biopsy

Liquid biopsy and surgical biopsy are two methods used to obtain tissue samples for medical diagnosis, but they differ significantly in several aspects:

A. Procedure:

- Liquid Biopsy: Involves the analysis of blood or other bodily fluids (like urine or cerebrospinal fluid) to detect circulating tumor cells (CTCs), cell-free DNA (cfDNA), or other biomarkers shed by tumors.
- Surgical Biopsy: Involves the surgical removal of tissue samples directly from the tumor site or affected area.

B. Invasiveness:

- Liquid Biopsy: Generally less invasive compared to surgical biopsy as it only requires a blood draw or fluid sample.
- Surgical Biopsy: Involves a surgical procedure, which carries inherent risks such as bleeding, infection, and damage to surrounding tissues.

C. Sample Availability:

- Liquid Biopsy: Can be performed more frequently and easily, allowing for serial monitoring of

disease progression or treatment response.

- Surgical Biopsy: Limited by the accessibility of the tumor site and the need for a surgical procedure, making it less feasible for frequent monitoring.

D. Accuracy:

- Liquid Biopsy: May have lower sensitivity and specificity compared to surgical biopsy, especially for early-stage cancers or specific tumor subtypes.
- Surgical Biopsy: Generally considered the gold standard for diagnosis due to the ability to obtain intact tissue samples directly from the tumor.

E. Cost and Time:

- Liquid Biopsy: Often quicker and less expensive than surgical biopsy, especially considering the absence of the need for anesthesia and hospitalization.
- Surgical Biopsy: Typically more costly and time-consuming due to the need for surgical facilities, anesthesia, and recovery time.

F. Applications:

- Liquid Biopsy: Particularly useful for monitoring disease progression, detecting minimal residual disease, identifying treatment-resistant mutations, and assessing treatment response.
- Surgical Biopsy: Essential for obtaining tissue samples for histological analysis, determining tumor grade and subtype, guiding treatment decisions, and conducting molecular profiling.



5. Quantitative aspects and statistics

A. Sensitivity: Liquid biopsy technologies have been striving to achieve higher sensitivity levels, with some techniques claiming to detect mutations present in as low as 0.01% of circulating tumor DNA (ctDNA) within a sample.

B. Mutation Detection Rates: Studies have reported mutation detection rates ranging from 50% to over 90% in various cancer types using liquid biopsy approaches, depending on factors such as tumor stage, tumor type, and the specific technology used.

C. False Positive Rates: False positive rates for liquid biopsy assays vary depending on the specific methodology and the biomarkers targeted. For example, false positive rates for detecting circulating tumor DNA (ctDNA) mutations can range from less than 1% to around 10%.

D. Cost per Test: The cost per liquid biopsy test can vary widely depending on factors such as the technology used, the complexity of the assay, and the volume of tests conducted. Estimates suggest that liquid biopsy tests can range from a few hundred to several thousand dollars per test.

E. Turnaround Time: Turnaround time for liquid biopsy tests can vary from a few days to a couple of weeks, depending on the specific assay and the laboratory conducting the analysis.

F. Market Size: The global liquid biopsy market was projected to grow significantly, with estimates varying between $1.5 billion to $3.5 billion by 2025, depending on different reports and market analyses.

G. Cancer Applications: Liquid biopsy was primarily being researched and applied in oncology, with estimates suggesting that approximately 80% of liquid biopsy research and applications were related to cancer detection, monitoring, and treatment response.

H. Clinical Trials: There was a notable increase in the number of clinical trials incorporating liquid biopsy technologies. These trials spanned various cancer types and aimed to validate the clinical utility of liquid biopsy for early detection, treatment monitoring, and prognosis.

I. Adoption Rate: While liquid biopsy was gaining traction in research settings, its adoption into routine clinical practice varied across regions and healthcare systems. Some advanced cancer centers and academic institutions were early adopters, while broader implementation faced challenges related to regulatory approval, reimbursement, and standardization.

J. Technology Evolution: Liquid biopsy technologies were rapidly evolving, with continuous improvements in sensitivity, specificity, and scalability. Next-generation sequencing (NGS) platforms were widely used for analyzing circulating tumor DNA (ctDNA), but other technologies such as digital PCR and mass spectrometry were also gaining prominence.

6. Technologies and Methods

The success of liquid biopsy relies on the development of sensitive and accurate technologies for detecting and analyzing tumor-derived biomarkers in complex biological fluids. Techniques such as digital droplet PCR (ddPCR), droplet digital PCR (ddPCR), and single-cell sequencing have significantly advanced the field by enabling the detection of rare mutations and genetic alterations present in CTCs and cfDNA. Moreover, advancements in microfluidics, nanotechnology, and

bioinformatics have further enhanced the sensitivity, specificity, and throughput of liquid biopsy assays, paving the way for their widespread adoption in clinical settings.

The technologies and methods of liquid biopsy encompass a variety of techniques used to isolate, detect, and analyze circulating tumor biomarkers present in bodily fluids such as blood, urine, and cerebrospinal fluid. These techniques have evolved over time to improve sensitivity, specificity, and throughput, enabling the widespread adoption of liquid biopsy in clinical practice. Here's an explanation of some key technologies and methods used in liquid biopsy:

A. Polymerase Chain Reaction (PCR):

- PCR is a widely used technique that amplifies specific DNA sequences present in a sample.
- In liquid biopsy, PCR-based methods, such as quantitative PCR (qPCR) and digital PCR (dPCR), are used to detect and quantify circulating tumor DNA (ctDNA) and other genetic alterations present in bodily fluids.
- These methods offer high sensitivity and specificity for detecting rare mutations and genetic alterations in liquid biopsy samples.

B. Next-Generation Sequencing (NGS):

- NGS is a high-throughput sequencing technology that enables the simultaneous sequencing of millions of DNA fragments.
- In liquid biopsy, NGS-based methods, such as targeted sequencing and whole-genome sequencing, are used to analyze the entire genome or specific genomic regions of circulating tumor DNA (ctDNA) and other biomarkers.
- NGS allows for the comprehensive profiling of tumor genomes, including the detection of single nucleotide variants (SNVs), copy number alterations (CNAs), and structural variations.

C. Digital Droplet PCR (ddPCR):

- ddPCR is a digital PCR technique that partitions a sample into thousands of individual droplets, each containing a single DNA molecule.
- In liquid biopsy, ddPCR is used to quantify rare mutations and genetic alterations present in circulating tumor DNA (ctDNA) and other biomarkers with high precision and sensitivity.
- ddPCR offers absolute quantification of target DNA molecules, making it particularly useful for detecting low-frequency mutations and monitoring treatment response in liquid biopsy samples.

D. Single-Cell Sequencing:

- Single-cell sequencing techniques enable the sequencing of individual cells, providing insights into the genetic heterogeneity of tumors.
- In liquid biopsy, single-cell sequencing can be used to analyze circulating tumor cells (CTCs) and characterize their genomic profiles at the single-cell level.
- This approach allows for the identification of rare subpopulations of tumor cells, the detection of clonal evolution, and the assessment of tumor heterogeneity in liquid biopsy samples.

E. Microfluidics and Nanotechnology:

- Microfluidic devices and nanotechnology-based approaches are used to isolate and analyze circulating tumor biomarkers with high efficiency and sensitivity.
- Microfluidic platforms enable the isolation and capture of circulating tumor cells (CTCs) from complex biological fluids, such as blood, based on their physical and biological properties.
- Nanotechnology-based assays, such as nanoparticle-based sensors and probes, can be used to detect and quantify circulating tumor DNA (ctDNA) and other biomarkers with high sensitivity and specificity.

F. Bioinformatics:

- Bioinformatics tools and algorithms are essential for processing and analyzing the large volumes of data generated by liquid biopsy assays.
- Bioinformatics pipelines are used to identify and annotate genetic variants, assess their clinical significance, and interpret their implications for cancer diagnosis and treatment.
- These tools enable the integration of genomic data from liquid biopsy samples with clinical information to guide personalized treatment decisions and monitor disease progression.

7. Clinical Applications

Liquid biopsy holds immense promise for a wide range of clinical applications in oncology, including early cancer detection, monitoring of treatment response, detection of minimal residual disease, and guiding personalized treatment decisions. Studies have demonstrated the utility of liquid biopsy in various cancer types, including lung cancer, breast cancer, colorectal cancer, and prostate cancer, among others. By providing real-time, non-invasive insights into tumor dynamics and evolution, liquid biopsy has the potential to revolutionize cancer management and improve patient outcomes.

Clinical applications of liquid biopsy:

- **Early Cancer Detection:** Liquid biopsy enables the detection of circulating tumor cells (CTCs) and cell-free DNA (cfDNA) shed by tumors into the bloodstream, allowing for early detection of cancer before symptoms manifest.
- **Monitoring Treatment Response:** By analyzing changes in circulating tumor biomarkers over time, liquid biopsy can assess treatment response, detect treatment resistance, and guide adjustments to therapy.
- **Detection of Minimal Residual Disease (MRD):** Liquid biopsy can detect residual tumor cells or tumor DNA in patients who have undergone treatment, aiding in the early detection of disease recurrence and informing treatment decisions.
- **Guiding Personalized Treatment Decisions:** Liquid biopsy provides real-time molecular profiling of tumors, allowing for the identification of specific genetic mutations or alterations that can guide targeted therapy selection and personalized treatment plans.
- **Assessment of Tumor Heterogeneity:** Liquid biopsy captures the genetic diversity of tumors by sampling circulating tumor biomarkers from different tumor sites, providing insights into tumor heterogeneity and evolution over time.
- **Prognostic and Predictive Biomarkers:** Liquid biopsy biomarkers, such as circulating tumor DNA

(ctDNA) mutations or levels of circulating tumor cells (CTCs), can serve as prognostic indicators or predictive biomarkers for patient outcomes and treatment response.

- **Minimal Invasive Monitoring:** Liquid biopsy offers a minimally invasive alternative to traditional tissue biopsies, reducing patient discomfort and the risk of complications associated with invasive procedures
- **Real-time Monitoring of Disease Progression:** Liquid biopsy allows for longitudinal monitoring of disease progression and treatment response, providing clinicians with real-time insights into tumor dynamics and evolution.
- **Complementary Diagnostic Tool:** Liquid biopsy can complement existing diagnostic modalities, such as imaging and tissue biopsies, by providing additional molecular information about the tumor's genetic makeup and evolution.
- **Clinical Trials and Research:** Liquid biopsy is increasingly used in clinical trials to assess treatment efficacy, monitor disease progression, and identify potential biomarkers for novel therapies, accelerating the pace of cancer research and drug development.

8. Challenges and Limitations

Despite its promise, liquid biopsy faces several challenges and limitations that need to be addressed for its widespread implementation in clinical practice. These include issues related to sensitivity, specificity, standardization, reproducibility, cost-effectiveness, and accessibility. Moreover, ethical considerations surrounding patient consent, privacy, and data sharing must be carefully addressed to ensure the responsible and ethical use of liquid biopsy technologies.

challenges and limitations of liquid biopsy

Sensitivity:

- Challenges exist in achieving sufficient sensitivity to detect low levels of circulating tumor biomarkers, especially in early-stage cancer or minimal residual disease scenarios.

Specificity:

- Differentiating tumor-derived biomarkers from non-tumor sources (e.g., normal cells, benign conditions) presents a challenge, leading to potential false-positive results.

Tumor Heterogeneity:

- Liquid biopsy may not fully capture the genetic heterogeneity of tumors due to sampling bias or incomplete shedding of tumor biomarkers into circulation.

Standardization:

- Lack of standardized protocols and assays for liquid biopsy hinders comparability and reproducibility of results across studies and clinical laboratories.

Reproducibility:

- Variability in sample collection, processing, and analysis methods can affect the reproducibility of liquid biopsy results, leading to inconsistencies in clinical interpretation.

Cost-effectiveness:

- The cost of liquid biopsy assays and associated technologies may limit their accessibility, particularly in resource-constrained healthcare settings.

Accessibility:

- Limited availability of liquid biopsy assays and expertise in certain regions or healthcare facilities

may restrict patient access to this diagnostic modality.

Clinical Validation:

- Further clinical validation is needed to establish the clinical utility and predictive value of liquid biopsy biomarkers across different cancer types and disease stages.

Ethical Considerations:

- Ethical considerations surrounding patient consent, privacy, and data sharing need to be carefully addressed to ensure the responsible and ethical use of liquid biopsy technologies.

Regulatory Approval:

- Regulatory approval and reimbursement policies for liquid biopsy assays may vary between countries and healthcare systems, impacting their adoption and integration into clinical practice.

9. Current Research Trends

Recent advances in liquid biopsy research have focused on the development of novel biomarkers, improved detection methods, and emerging technologies. Researchers are exploring the potential of liquid biopsy in new disease areas beyond cancer, such as infectious diseases, autoimmune disorders, and prenatal testing. Moreover, efforts are underway to integrate liquid biopsy with other diagnostic modalities, such as imaging and pathology, to provide a more comprehensive understanding of disease biology and improve patient care.

As of January 2022, liquid biopsy research trends were focused on improving detection sensitivity, expanding applications beyond cancer to include infectious diseases and transplant monitoring, and developing standardized protocols for clinical implementation. Researchers were also exploring novel biomarkers and platforms for liquid biopsy analysis, such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), extracellular vesicles, and microRNAs. Advancements in technologies like next-generation sequencing (NGS), digital PCR, and mass spectrometry were driving progress in liquid biopsy research.

10. Future Directions

Looking ahead, the future of liquid biopsy holds immense promise for transforming cancer diagnosis and management. Continued research efforts are needed to address existing challenges and limitations, improve the sensitivity and specificity of liquid biopsy assays, and expand its clinical utility across different cancer types and disease stages. Moreover, collaborations between researchers, clinicians, industry partners, and regulatory agencies will be crucial for driving innovation, standardizing protocols, and ensuring the responsible implementation of liquid biopsy technologies in clinical practice.

In the future, we can expect continued advancements in liquid biopsy technologies, leading to improved sensitivity, specificity, and cost-effectiveness. These advancements may facilitate early detection, monitoring of treatment response, and detection of minimal residual disease in various conditions, including cancer, infectious diseases, and transplant rejection. Integration of artificial intelligence and machine learning algorithms into liquid biopsy data analysis could enhance interpretation and clinical utility. Moreover, as research progresses, we may see more widespread adoption of liquid biopsy in routine clinical practice, potentially transforming how we diagnose and manage diseases.

11. Conclusion

In conclusion, liquid biopsy represents a paradigm shift in cancer diagnosis and management, offering a non-invasive, real-time, and comprehensive approach to understanding tumor biology and guiding personalized treatment decisions. While challenges and limitations remain, ongoing research efforts and technological advancements continue to drive the field forward, holding the promise of improving patient outcomes and advancing our understanding of cancer biology. As we embark on this exciting journey towards realizing the full potential of liquid biopsy, collaboration and innovation will be key to harnessing its power for the benefit of patients worldwide.

12. References

1. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol. 2013;10(8):472-484. doi:10.1038/nrclinonc.2013.110
2. Wan JCM, Massie C, Garcia-Corbacho J, et al. Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer. 2017;17(4):223-238. doi:10.1038/nrc.2017.7
3. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531-548. doi:10.1038/nrclinonc.2017.14
4. Diaz LA Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol. 2014;32(6):579-586. doi:10.1200/JCO.2012.45.2011
5. Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease—latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409-424. doi:10.1038/s41571-019-0196-y
6. O'Leary B, Hrebien S, Morden JP, et al. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer. Nat Commun. 2018;9(1):896. doi:10.1038/s41467-018-03215-x
7. Riva F, Bidard FC, Houy A, et al. Patient-specific circulating tumor DNA detection during neoadjuvant chemotherapy in triple-negative breast cancer. Clin Chem. 2017;63(3):691-699. doi:10.1373/clinchem.2016.263798
8. Diehl F, Schmidt K, Choti MA, et al. Circulating mutant DNA to assess tumor dynamics. Nat Med. 2008;14(9):985-990. doi:10.1038/nm.1789
9. Dawson SJ, Tsui DW, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368(13):1199-1209. doi:10.1056/NEJMoa1213261
10. Tie J, Wang Y, Tomasetti C, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92. doi:10.1126/scitranslmed.aaf6219
11. Newman AM, Lovejoy AF, Klass DM, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol. 2016;34(5):547-555. doi:10.1038/nbt.3520
12. Garcia-Murillas I, Schiavon G, Weigelt B, et al. Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med. 2015;7(302):302ra133. doi:10.1126/scitranslmed.aab0021
13. Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446-451. doi:10.1038/nature22364

14. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med. 2012;4(136):136ra68. doi:10.1126/scitranslmed.3003726
15. Sacher AG, Paweletz C, Dahlberg SE, et al. Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer. JAMA Oncol. 2016;2(8):1014-1022. doi:10.1001/jamaoncol.2016.0173
16. Tie J, Cohen JD, Wang Y, et al. Serial circulating tumor DNA (ctDNA) analysis of colon cancer patients treated with chemotherapy reveals diverse and rapid emergence of resistant clones. Ann Oncol. 2016;27(8):1538-1546. doi:10.1093/annonc/mdw224
17. Phallen J, Sausen M, Adleff V, et al. Direct detection of early-stage cancers using circulating tumor DNA. Sci Transl Med. 2017;9(403):eaan2415. doi:10.1126/scitranslmed.aan2415
18. Siravegna G, Mussolin B, Buscarino M, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med. 2015;21(7):827-829. doi:10.1038/nm.3870
19. Oxnard GR, Thress KS, Alden RS, et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J Clin Oncol. 2016;34(28):3375-3382. doi:10.1200/JCO.2016.66.7162
20. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14(9):531-548. doi:10.1038/nrclinonc.2017.14
21. Certainly! Here are 10 references related to liquid biopsy research and clinical applications in India:
22. Rajkumar T, Vijayalakshmi N, Sabitha K, et al. Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer. 2011;11:80. doi:10.1186/1471-2407-11-80
23. Mandal P, Kandikattu HK, Mishra N, et al. Circulating nucleic acids and non-coding RNAs as potential biomarkers for liquid biopsy in gastrointestinal cancers. Semin Cancer Biol. 2021;74:137-153. doi:10.1016/j.semcancer.2020.07.019
24. Patil M, Bhaumik S, Babu N, Kumar DS. Concentration, composition and diagnostic potential of exosomes in cancer. J Cancer Sci Ther. 2015;7(2):01-05. doi:10.4172/1948-5956.1000337
25. Ghosh AK, Basu A. Circulating microRNAs: a promising role in diagnosis, prognosis, and therapeutic targets for hepatocellular carcinoma. Clin Biochem. 2018;58:109-118. doi:10.1016/j.clinbiochem.2018.07.009
26. Jain P, Jain SK, Bose D. Liquid biopsy: a new dawn for the detection of urothelial carcinoma. J Clin Diagn Res. 2020;14(9):ZC65-ZC68. doi:10.7860/JCDR/2020/45898.13938
27. Rastogi A, Mehta A, Bhalla K, et al. Assessment of tumor cell-free DNA (cfDNA) in Indian breast cancer patients. Clin Chim Acta. 2020;507:142-150. doi:10.1016/j.cca.2020.04.025
28. Dey S, Sharma V, Gupta V, Kishore A. Genetic alterations in Indian metastatic breast cancer patients: identification of novel candidates for liquid biopsy. Mol Biol Rep. 2020;47(6):4529-4541. doi:10.1007/s11033-020-05499-x
29. Chakraborty C, Sharma AR, Sharma G, Doss CGP, Lee SS. Therapeutic miRNA and siRNA: moving from bench to clinic as next generation medicine. Mol Ther Nucleic Acids. 2017;8:132-143. doi:10.1016/j.omtn.2017.06.005
30. Deolalikar S, Gazdar A, Tadwalkar S, et al. Genomic markers for head and neck cancer in Indian population: a step towards personalizing medicine. Mol Biol Rep. 2019;46(4):4077-4086. doi:10.1007/s11033-019-04761-3

31. Choudhary G, Govindarajulu M, Bojanapalli S, Pattnayak NC, Patel S. Liquid biopsy: the next-generation genome-guided oncology. Trends Cancer Res. 2019;15:1-22.